Investor Insights with Terri Burke: What Do You Expect to See in MedTech in 2026?

In this market-focused segment, Ken Dropiewski asks Terri Burke for her outlook on MedTech funding in 2026. Terri shares that while 2025 felt challenging, the data suggests it was stronger than many perceived, with capital still skewed toward later-stage investments following the insider-heavy rounds of recent years. She notes continued pressure on Series B companies—particularly those past proof of concept but not yet through first-in-human or EFS—while highlighting longer exit timelines and valuation resets as ongoing realities. Despite this, Terri points to renewed acquisition activity as a positive signal, expressing cautious optimism that momentum is building heading into 2026.